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Abstract
Background: The outbreak of the 2009 H1N1 influenza pandemic (H1N1pdm) affected thousands of people in Mexico
and the United States, and spread rapidly throughout the world from April 2009 to July 2010. To explore the age-specific
prevalence of seroprotection against H1N1pdm infection, we estimated pre-existing humoral and cellular immunities of
residents in Northern China against H1N1pdm and seasonal H1N1 virus in an age-dependent manner.
Methods: Anonymous serum samples were collected from 1425 to 1434 adult healthy individuals before and after the
pandemic outbreak, and then grouped by birth year 1913–1990. The antibody titers of H1N1pdm and seasonal
H1N1 were determined using microneutralization (MN) assays, and the proportion of seropositive was estimated
based on the year of birth. Separately, another 63 blood samples were collected in 2006 and prepared for analysis of
virus specific memory B and IFN-γ+ T cells using the ELISpot assays.
Results: The prevalence of pre-existing H1N1pdm-specific sero-antibodies in the elderly population (>60 years old) was
7.8%. The younger group, aged 19 to 60 years, exhibited a significant increase in seropositivity for H1N1pdm after the
pandemic (4.9% before pandemic and 18.9% after pandemic, p < 0.05). The prevalence of H1N1pdm specific MBCs
before the pandemic in the elderly (>60 years) and younger populations (<60 years) was 38% (8/21) and 48% (20/42),
respectively (p = 0.6). The IFN-γ+ T cell responses to the pandemic and seasonal viruses were significantly lower in the
elder group than those in the younger group (<60 years) (p < 0.05).
Conclusions: Pre-existing serum antibodies and memory B cells against H1N1pdm were low in all age group, whereas
diminished memory T cell responses to this virus were observed in the elderly population both before and after
the pandemic.
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Background
In April 2009, an outbreak of H1N1 influenza initially
hit Mexico and rapidly spread to other countries and
regions of the world. On June 11, 2009, World Health
Organization (WHO) declared the first state of emer-
gency about the influenza pandemic in 21st century [1].
Historically, there were four worldwide pandemics of
influenza which had caused millions of death. The first
influenza pandemic in 1918 which caused by H1N1
strain killed 40 to 50 million people [2]. In 1957, the
prevalent strain of influenza virus H1N1 in human
abruptly disappeared and replaced by a new reassortant
of influenza virus H2N2, which contained three new seg-
ments from the avian source and maintained the other
five segments from the H1N1 strain of 1918 lineage [3].
In 1968, the circulating influenza virus H2N2 subtype
transformed to H3N2 subtype by reassortment of the
novel hemagglutinin (HA) and polymerase PB1 seg-
ments [4]. In January 1976, a novel virus subtype, A/
New Jersey/76 H1N1, was identified in an outbreak of
respiratory disease occurred among soldiers returning to
an Army base in Fort Dix, New Jersey. However, this
virus subtype did not escape from the base [5]. In 1977,
separate emergence of another H1N1 virus successfully
propagated [6], and then co-circulated with 1968 H3N2
subtype in human population globally. The 2009 pan-
demic H1N1 virus (H1N1pdm) was antigenically similar
to pre-1950 influenza strains [7] and A/New Jersey/76
H1N1 strain [8].
The prevalence of pre-existing memory B cell against
2009 H1N1pdm in human population has been rarely
evaluated. The ELISpot assay had been developed to
count antigen-specific memory B cells in human blood
by Crotty et al. [9]. These detected antigen specific
memory B cells satisfied the canonical surface phenotype
of human memory B cells: CD19+CD20+Ig+CD27+ [9].
This method had been widely used to assess the
immunological memory of B cells response to various
infectious diseases [10].
As estimated in China and other countries, overall
age-standardized H1N1pdm cumulative incidence varied
significantly by age with the highest in children 5–19
and 0–4 years old [11]. This age distribution was differ-
ent from the seasonal influenza which mostly infected
the elderly population [12]. In the present study, we
evaluated neutralization antibodies against H1N1pdm as
well as recent circulating seasonal H1N1 viruses in
serum samples collected before and after the pandemic.
The samples were further resorted by birth year to esti-
mate the age-specific H1N1pdm infection. In addition,
we examined H1N1pdm and seasonal H1N1 specific
memory B and IFN-γ+ T cells frequencies using ELISpot
assay in healthy individuals, whose blood had been col-
lected in 2006, and aimed to evaluate the potential
connections of pre-existing cellular immunities and age-
dependent H1N1pdm influenza infections.
Methods
Ethics statement
The research involving human materials was approved
by Institutional Review Board at the China Center for
Disease Control and Prevention. The study was per-
formed anonymously and with the written informed
consent provided by the participants.
Sero-epidemiological study before and after the
pandemic influenza A (H1N1) 2009 virus outbreak
Serum sample collections
We recruited adult volunteers (≥20 years old) from 1)
health examination individuals from a big health examin-
ation center in Beijing 2) employee annual health check-
up from one national department in Beijing China.
H1N1pdm firstly emerged in May and reached peak in
November, 2009, according to influenza surveillance in
Beijing [13]. Serum samples from 1425 individuals pre-
pandemic were collected from June, 2008 to April, 2009,
and 1434 serum samples post-pandemic were collected
from January to July 2010. During serum samples collec-
tion, seasonal influenza H1N1 prevailed from October
2008 to April 2009 [14], and followed with the epidemic
of seasonal H3N2 from mid-July to late-September 2009
in Beijing [15]. The information of collection date, age and
gender was provided as appendix in the end (Additional
file 1: Table S1).
Viral preparation
Seasonal influenza A/Brisbane/59/2007 and 2009 pan-
demic influenza A/California/07/2009 viruses were
kindly provided by Dr. YL Shu, Chinese National Influ-
enza Center, and propagated in embryonated chicken
eggs. The allantoic fluid containing viruses were col-
lected, filtered and stored in aliquots at −70 °C. Virus
titers were determined by EID50 (50% egg infectious
dose), TCID50 (50% tissue culture infectious dose) and
PFU (plaque forming units) in Madin Darby Canine
Kidney (MDCK) cells.
Serological assays
Microneutralization assay (MN) As previously reported
[16], heat inactivated sera were serial 2-fold diluted, and
then preincubated with an equal volume of A/California/
07/2009 (H1N1) or A/Brisbane/59/2007 (H1N1) influenza
virus in 96 well plates. After 1 h incubation, the virus-
serum mixtures were added in the monolayer of MDCK
cells, and continued with incubation at 37 °C and 5% CO2
for another 18–20 h. The monolayer cells were washed
and fixed. The presence of viral protein was detected by
ELISA with the influenza NP monoclonal antibody (kindly
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provided by Dr. Adam Meijer., National Institute for Pub-
lic Health and the Environment, Netherlands). The
neutralization endpoint titer was calculated as described
in detail by Rowe T et al. [16]. The antibody titer >40 was
taken as equivalent of seropositivity.
Hemagglutination inhibition assay (HI) All sera were
treated with receptor destroying enzyme (RDE) and
heat-inactivation, and absorbed with the chicken eryth-
rocytes to remove non-specific hemagglutination. The
HI assay was performed as the WHO recommended
protocol [17]. The HI titer was defined as the reciprocal
of the last dilution of serum samples that completely
inhibited hemagglutination.
A subtotal of 648 samples were tested by both MN
and HI assays. Spearman’s rank correlation analysis had
demonstrated a good correlation of the both assays to
seasonal and pandemic influenza viruses (f = 0.745 and
0.786, respectively, p < 0.0001). Thus, MN assay was
used solely to test the remained samples.
Pre-existing human memory B cells and IFN γ+-T cells to
pandemic influenza A (H1N1) 2009
Peripheral blood mononuclear cell (PBMC) samples
The PBMCs were isolated from 63 healthy residents
(aged from 20 to 90 years) of a village in Northern
China, collected in early November, 2006 as a part of
routine influenza surveillance program (before 2006–2007
seasonal influenza epidemic). The enrolled criterion in-
cluded no influenza vaccination in the past 5 years, no
autoimmune disease such as systemic lupus erythemato-
sus (SLE) or rheumatoid arthritis (RA), and without
ongoing immunosuppressive treatment. PBMCs stored in
liquid nitrogen were thawed and cultured in warm
RPMI 1640 complete medium supplied with 10% FBS,
penicillin/streptomycin and L-glutamine (HyClone,
Thermo Scientific, USA) before the ELISpot assays of
memory B cells and IFN γ+-T cells.
IgG+ memory B cell assay (MBC)
The IgG+ memory B cell assay, which required the stimu-
lation of memory B cells to antibody secreting cells (ASC),
was performed as previously described by Crotty et al. [9]
and successfully established in our lab (Additional file 2:
Figure S1). Briefly, PBMCs were cultured for 5 to 6 days
in the presence of a mix of polyclonal mitogens, including
pokeweed mitogen extract (kindly provided by Prof. Shane
Crotty, La Jolla Institute for Allergy and Immunology, La
Jolla, CA), CpG oligonucleotide ODN-2006 (SANGON,
Shanghai, China), and fixed S.aureus, Cowan (SAC,
Sigma-Aldrich, Co. St Louis. MO). To determine HA-
specific MBCs, ELISpot plates (Millipore, Billerica, MA)
were pre-coated overnight with influenza HA antigen
(2 μg/mL) of A/California/07/2009 or A/Brisbane/59/2007
strain (eENZYME, LLC. Montgomery Village, MD) and
then blocked by incubation with 2% BSA in PBS for 1–2 h
at 37 °C. The stimulated PBMCs were added into coated
plates as described and incubated for 6 h at 37 °C. The
captured MBCs were detected by donkey anti-human IgG
Fc biotin conjugated antibody (Jackson immunoresearch
laboratories, Inc.), followed by streptavidin-alkaline phos-
phatase (ALP) (Vector Laboratories, Inc. Burlingame,
CA) and developed by alkaline phosphatase substrate
kit (Vector Laboratories, Inc.). The keyhole limpet
hemocyanin (KLH, 2 μg/mL) (Sigma) coated in plate was
considered as the negative control antigen. The donkey
anti-human Ig (Jackson immunoresearch laboratories, Inc.
West Grove, PA) coated in plate was used to enumerate
total IgG+ MBCs of PBMCs. The frequency of HA-
specific MBCs was defined as the proportion of HA-
specific MBCs in the total IgG+ MBCs. The samples
were scored positive if the frequency of HA-specific
MBCs was higher than that of negative control coated
with KLH.
IFN-γ+ ELISpot
The 96-well ELISpot plates were pre-coated with IFN-γ
mAb (Mabtech, Stockholm, Sweden) and blocked with
RPMI 1640 supplied with 1% BSA overnight at 4 °C. A
total of 5 × 105 cells/well PBMCs suspended in RPMI
1640 medium with the supplement of 2.5% BSA, penicil-
lin/streptomycin and L-glutamine) were infected with ei-
ther influenza virus A/California/07/2009 or A/Brisbane/
59/2007 (suspended in media RPMI 1640 media with
2.5% BSA) at a multiplicity of infection (MOI) of 1 or 2.
Plates were incubated overnight at 37 °C. The infected
PBMCs were added into pre-coated plates as described
previously and incubated for 6 h at 37 °C, followed by
washing and detection with biotinylated secondary
monoclonal antibody (7-B6-1, Mabtech) and ALP sub-
strate kit (Vector Laboratories). Background was deter-
mined in cultures containing media alone, or allantoic
fluid from mock-infected eggs at the same gestational
age. Phytohemagglutinin (PHA, 10 μg/mL) was used as
the positive control. The numbers of spots in each well
were counted by an automated CTLtd ELISpot plate
reader (Cellular Technology Ltd. Shaker Heights, OH)
and results were presented as spot-forming cells (SFC)
in per million PBMCs.
Statistic analysis
Statistical analysis was performed in SPSS statistical pack-
age version 19.0 (SPSS, Chicago, IL, USA). Basic means
and percentages were calculated. Data of HA-specific
MBCs and IFN-γ+ T cells were presented as dot plot of
the raw data overlaid by box-and-whisker plot (median,
first and third percentile, range). Paired t-test was used to
compare pre-existing B or T cell immunity between
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seasonal and pandemic influenza infections. P value <0.05
was considered as statistical significance.
Results
A total of 1425 and 1434 un-paired serum samples were
collected pre- and post-pandemic, respectively. Separately,
another set of PBMCs from 63 individuals were collected
before the pandemic and used for the cell immunity assays
(Additional file 1: Table S1).
Birth year-dependent seroprevalence of A (H1N1)pdm
2009 and seasonal influenza
Before the pandemic, the estimated proportion of sero-
positive to 2009 H1N1pdm virus was generally as low as
5.9% across the population studied (Fig. 1a and c).
Although elder people over 60 years of age had a higher
seroprevalence (7.8%) than younger people under
60 years (4.9%, p = 0.035) before the pandemic, there
were no significant difference of geometric mean titers
(GMT) between the elder people (12, 95% CI: 12–13)
and the younger people (11, 95% CI: 11–12; p = 0.07).
After the first wave of pandemic in Beijing, the overall
seropositive against pandemic H1N1 virus increased to
16.3%. In addition, the proportion of seropositives to the
2009 H1N1pdm virus in younger people under 60 years
old (18.9%) was significantly higher than the proportion
in people over 60 years old (11.9%, p = 0.001). Moreover,
the GMTs in the younger group (17, 95% CI: 16–18)
were significant higher than in the elder people group
(14, 95% CI: 13–15; p < 0.001) (Fig. 1a, c). Overall, the
significant increased titers against 2009 H1N1pdm virus
was observed in people born after 1950s (younger than
60 years old) (p < 0.05).
Differently, there were significant higher proportion of
seropositives and GMTs against seasonal influenza (A/
Brisbane/59/2007) in older people over 60 than in
younger people under 60 years old regardless of the
2009 H1N1pdm [Positive rate: 42.1 vs. 27.3% pre-
pandemic, 57.7 vs. 45.8% post-pandemic; GMT: 33 (95% CI,
29–38) vs. 22 (95% CI, 20–24) pre-pandemic, 57 (95% CI,
Fig. 1 Antibody titers of A/California/07/2009 (2009 H1N1 pandemic influenza A) and A/Brisbane/59/2007 (H1N1 seasonal influenza A) viruses grouped
by birth year before (from June, 2008 to April, 2009) and after the pandemic (from January to July, 2010) in Beijing, China. a, b Geometric mean titers
(95% confidence intervals). c, d Percentage with microneutralization assay titers ≥40 (95% confidence intervals). Undetectable titer was set at the level of
10 for calculation of geometric mean titers. ≥60 years: equal and older than 60 years old; <60 years: younger than 60 years old. P value was calculated
between people over and under 60 years old※ before pandemic and☆ after pandemic
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49–64) vs. 35 (95% CI, 31–38) post-pandemic, respectively;
p < 0.001] (Fig. 1b, d). Furthermore, significantly increased
proportions of seropositive individuals and higher
microneutralization antibody titers against seasonal
influenza were observed both in the elder and the
younger group after the pandemic (p < 0.001) (Fig. 1b, d).
Birth year-dependent pre-existing memory B cells
The frequency profile of pre-existing MBCs from all the
63 samples (collected pre-pandemic) was exhibited as
scatter plots in Fig. 2a. Screening by ELISpot assay
showed that 28 samples (28/63, 44%) were positive for
H1N1pdm influenza HA specific MBCs (Fig. 2a).
Among the 28 MBCs positive samples (44.4%, 28/63), 8
samples (38%, 8/21) were from the individuals over
60 years old, while 20 (48%, 20/42) were from under
60 years old (Fisher Exact Test, p = 0.6). In general, low
proportions of pandemic influenza H1N1-specific MBCs
were observed across the studied groups.
For seasonal influenza, there were 33 samples (33/63,
52%) positive for HA specific MBCs, including 8 of 21
individuals (38%, 8/21) over 60 years and 25 of 42
individuals (60%, 25/42) under 60 years old (Fisher Exact
Test, p = 0.1). Up to 0.4% of circulating IgG+ memory B
cells were recognizing seasonal influenza (mean ± SE =
0.05 ± 0.01%) (Fig. 2a). The proportions of seasonal
influenza HA specific MBCs also didn’t show any signifi-
cant difference between the people over 60 and under
60 years old (p = 0.685) (Fig. 2a).
Birth year-dependent pre-existing IFN-γ+ T cells
The frequencies of IFN-γ+ SFC per million PBMCs
exhibited a relatively variable distribution with the
Fig. 2 The overall response patterns of pre-pandemic influenza specific B and IFN-γ+ T cell immunities from the same individual against pandemic
and seasonal H1N1 grouped by the year of birth. a Frequency of influenza hemagglutinin (HA) specific memory B cell as a percentage of the total
IgG+ memory B cells. MBCs, memory B cells. b Frequency of IFN-γ+ T cell per million PBMCs stimulated with live influenza viruses. The data were
presented as dot plot of the raw data, overlaid by box-and-whisker plot (median, first and third percentile, range). Blank circle point in red represents
as the positive for HA specific MBCs of H1N1 pdm. Pandemic H1N1, A/California/07/2009 (H1N1). Seasonal H1N1, A/Brisbane/59/2007 (H1N1).
The horizontal line in each column indicates the median value. ≥60 years: equal and older than 60 years old; <60 years: younger than 60 years
old. P value was calculated between people over and under 60 years old △stimulate with pandemic and ◆seasonal influenza virus
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stimulation of live influenza viruses (Fig. 2b). For both
the viruses, the magnitudes of T cell response in the
elderly participants over 60 years (seasonal influenza:
mean ± SE = 28 ± 10; H1N1pdm influenza: mean ± SE =
18 ± 4) were significantly lower than those in younger
participants under 60 years old (seasonal influenza:
mean ± SE = 61 ± 12; H1N1pdm influenza: mean ± SE =
45 ± 8) (t-test, p = 0.008, p = 0.04 respectively) (Fig. 2b).
Although there were no statistical differences of the
proportions of IFN-γ+ T cell positive individuals be-
tween seasonal influenza H1N1 (91%, 57/63) and
H1N1pdm (86%, 54/63) among the total subjects
(Fisher Exact Test, p = 0.6), the overall magnitudes of
IFN-γ+ SFC against seasonal influenza (mean ± SE = 47
± 8) were significantly higher than those against
H1N1pdm (mean ± SE = 34 ± 5) (Paired T-Test, p =
0.02).
Discussion
Compared with other countries [2, 18–21], elderly
people in China had a relatively low baseline of antibody
production responding to the 2009 H1N1pdm [22, 23].
In a serosurvey of large samples (n = 2379), only 2.0%
elder Chinese people had pre-existing antibodies
responding to H1N1pdm virus [22]. In the present
study, our data further demonstrated a relatively low fre-
quency of pre-existing H1N1pdm virus-specific MBCs in
the elderly population in China. It was not fully under-
stood why Chinese elder people had a lower infection
rate than the youth during the 2009 H1N1pdm.
The pre-existing CD8+ T lymphocytes (CTL) memory
can mediate heterologous immunity among different
subtype influenza A viruses [24]. Although recent sea-
sonal influenza induced little cross-reactive antibody
production against H1N1pdm virus [21], cellular
responses might provide immune protection by targeting
invariable or cross-reactive epitopes. A total of 49% of
the epitopes in recent seasonal H1N1 were found totally
conserved in H1N1pdm [25], furthermore, CD8+ T cells
specific for conserved epitopes could lyse pandemic
influenza infected cells in vitro [26]. One research indi-
cated that H1N1pdm virus shared immunogenic pep-
tides with the catastrophic 1918 H1N1 strain as well as
viruses circulating prior to 1945 [27]. Cross-reactive
CTL immunity between the H1N1pdm strain and the
1918 Spanish H1N1 strain might be related with the
lower susceptibility to 2009 H1N1pdm in people over
65 years of age [27]. Another recent study suggested that
high susceptibility of children to the pandemic H2N2 in
1957 might be more closely linked to the number of
influenza exposures [28].
Our study indicated that live influenza virus (both pan-
demic and seasonal influenza) stimulated poor responses
of IFN-γ+ T cells in the older population, consisting with
the other studies using peptide pools stimulation [29]. We
supposed the reduced T cell responses in the older group
might be due to aging of the immune system and reduced
responsiveness. Aging has a significant impact on CTL re-
sponses in murine model [30]. Not only naïve epitope-
specific CD8+ T cells decline with age [31], but also TCR
repertoire diversity decreases with age [32]. All these
reduced T cell function in the older individuals might lead
to underestimated response of magnitude in IFN-γ+ ELI-
Spot assay. It seemed that early priming of CTL response
prior to aging was the key for establishment of long-
lasting and protective immunity.
In our IFN-γ+ ELISpot assay, we used the live influ-
enza virus. It was important to understand the responds
of IFN-γ+ T cells to live virus, because these cells were
presumably reacting to processed virus from within
infected antigen presenting cells. With the use of live
virus, adequate epitopes through the natural infection of
APCs for the activation of virus specific IFN-γ+ T cells
could be generated [29, 33, 34]. However, it was difficult
to directly assess the HA specific humoral and cellular
immunity responses when using live virus to stimulate
APCs. Virus activated IFN-γ+ T cells could produce
kinds of pro-inflammatory cytokines or directly clear
virus from the infected cells, thus benefit to the rapid
recovery from influenza infection [35]. The influenza
virus specific IFN-γ+ T cells responses were mainly initi-
ated by conserved antigens (such as nucleoprotein and
M protein) and therefore the ELISpot assay could detect
the influenza virus with highly diverse subtypes [36].
Pre-existing sero-antibodies and memory B cells
against H1N1pdm virus were low across all studied
population. Although seropositives of H1N1pdm virus
was higher in people over 60 years than in ones under
60 years, the difference is too small (7.8 vs 4.9%) to
deduce one solid conclusion. Moreover, the GMT titers
were not significantly different between two age groups.
In contrast, sero-antibodies against seasonal influenza
H1N1 were higher in the elder than in the younger
people. The high seroantibody responses in the elderly
might be the results of high infection rate in this suscep-
tible population during the seasonal influenza season in
Northern China [37]. However, seasonal HA specific
MBC was not high in the older people. We proposed
that an impaired memory B cell response in the elderly
as observed in vaccination subjects might be one of the
plausibility [38]. However the real mechanism might be
much more complex. We observed that even with low
numbers of seasonal H1N1-specific MBCs elderly indi-
viduals maintained higher serum antibody levels than
younger people and theses were boosted after the pan-
demic wave. But this was not the case for pdmH1N1
where there were low padmH1N1-specific MBCs and
low serum antibody levels. The pattern of repeated
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exposure to seasonal strains in population might be ex-
pected as one of the explanations. However, it could not
fully explain the discrepant memory responses between
seasonal and pandemic influenza H1N1.
There were several limitations in the present study.
Firstly, the serum samples of pre and post-pandemic
were not well paired, and the vaccination history and
health status of participants were not identified. These
might yield biased prevalence of H1N1pdm in different
age groups. Secondly, the blood samples used for the
serological assays and cell immunity assays were not well
paired, and the number of samples used for cell immun-
ity assay was not enough to get the statistical power.
Thirdly, the lack of additional experiments to better
characterized the memory T or B cell responses (such as
CD45RA, CD45RO, CD4+IFN-γ+, CD8+ IFN-γ+), cyto-
kine profile under stimulation with influenza peptides,
and so on, due to the limited accessible samples, made
further evaluation of immune response impossible.
Conclusions
In conclusion, we demonstrated that the pre-existing
serum antibodies and specific memory B cells against
H1N1pdm were all low in studied Chinese population,
whereas in the elderly population, we observed a re-
duced memory T cell response both against pandemic
and seasonal influenza viruses pre- and post-pandemic.
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